Small Cap Feast

Small Cap Feast – 06 January 2021

Dish of the Day:

No joiners today

 

Off the Menu:

No leavers today

 

What’s Cooking in the IPO Kitchen?

Upon Admission to AIM, Nightcap will acquire The London Cocktail Club Limited (the “London Cocktail Club”), which is an award winning independent operator of ten individually themed cocktail bars in nine London locations and one location in Bristol. Offer TBC Due mid Jan.

HSS Hire Group, HSS.L transfer from Main to Aim. Mkt Cap c. £70m. Recently raised £52.6m. Leading supplier of tool and equipment for hire in the United Kingdom and Ireland and has provided equipment hire services in the United Kingdom for more than 60 years, primarily focusing on the B2B market.  Due 14 Jan.

VH Global Sustainable Energy Opportunities plc, a closed-ended investment Company focused on making sustainable energy infrastructure investments, today announces intends to launch an initial public offering  of shares on the Official List (Premium) of the Main Market of the London Stock Exchange.  Due by Early Feb.

 

Breakfast Buffet

Crossword Cybersecurity* 275p £14.1m (CCS.L)

The technology commercialisation company focused  on cyber security and risk management,   has  announced its first webinar panel discussion for 2021 , following the success of its 2020 series.  Taking place on Tuesday 12 January 2021 at 3pm, “Cyber Security: skills shortage, automation deficit or poor hiring practices – what’s the reality?” will bring together academics, customers and industry professionals to discuss one of the biggest challenges in the industry.

The discussion will be chaired by Dr Robert Nowill, Executive Chair of the Board at The Cyber Security Challenge, with a panel including Amanda Finch, CEO at The Chartered Institute of Information Security; Darren Argyle, CISRO at Standard Chartered Bank; and Stuart Jubb, Managing Director for Crossword Cybersecurity’s consulting division.

 

Seeing Machines 7.45p £278.42m (SEE.L)

The advanced computer vision technology company that designs AI-powered operator monitoring systems to improve transport safety, has advanced its previously announced Memorandum of Understanding to an executed License Agreement  to license the Company’s Occula® Neural Processing Unit to OmniVision Technologies, Inc..

This Agreement represents the first execution of the silicon license for Seeing Machines’ Occula®, which offers a unique NPU design that enables the development of low-cost, high-performance edge-AI to power future human-machine interfaces.

 

Rockfire Resources 1.075p £8.95m (ROCK.L)

The gold and base metal exploration company, announced that the Company’s recent helicopter geophysical survey has doubled the footprint of potential copper mineralisation at its 100%-owned Copperhead porphyry project in North Queensland, Australia .

The copper target is now defined by a minimum area of 5 km east-west x 3 km north-south. Faults and fractures are clearly defined and correlate well with known copper mineralisation already discovered in streams, soils, and drilling completed by Carpentaria Exploration in 1972.

The drilling in 1972 tested an area less than 0.6% of the expanded target area. The Copperhead target remains open in all directions. The price of copper has increased substantially from US$4,617 per tonne in March 2020 to US$7,964 per tonne in December 2020; an increase of 72.5% in the last 9 months.

Planned work at Copperhead over the next six months includes detailed prospect-scale mapping and soil/rock sampling within the expanded target area, with subsequent drilling.

 

Personal Group Holdings 206p £64.31m (PGH.L)

Personal Group PLC, a leading provider of employee services in the UK, announced that Sarah Mace, previously Interim Chief Financial Officer, has been appointed as Chief Financial Officer with immediate effect. 

Sarah was appointed to the board as Interim Chief Financial Officer on 1 October 2020, following a successful tenure at Personal Group since January 2014 when she joined as Group Financial Controller and Company Secretary.

 

Shearwater 157.5p £37.5m (SWG.L)

The organisational resilience group, announces that its group company, Brookcourt Solutions Limited (Brookcourt), has secured a five-year supply agreement with a global fashion retailer, headquartered in New York.

The first contract to be delivered under the supply agreement encompasses the delivery of a secure ID-authenticated printing solution as well as a 12-month maintenance and service contract, for use within ten European countries across 17 sites. The value of the first contract is £860 ,000, of which the majority is expected to be recognised in the current full year. This contract win underpins the Group’s current full year forecasts, with the supply agreement having the potential to deliver further revenue opportunities in future years.

 

Silence Therapeutics 537p £447m (SLN.L)

The specialist in the discovery,   development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced the appointment of Craig Tooman as the Company’s Chief Financial Officer (CFO) and member of the Executive Leadership Team, effective immediately.

 Mr. Tooman has a successful career in the biopharmaceutical industry spanning more than 30 years, including 15 years of experience as a public company CFO. Most recently, he was CFO and COO at Vyome Therapeutics, and prior to this was CFO and then CEO of Aratana Therapeutics where he successfully negotiated a merger with Elanco. Before Aratana, Mr. Tooman was the CFO of Enzon Pharmaceuticals until its acquisition by Sigma Tau, and prior to that led the $1.1 billion M&A initiative and integration of ILEX Oncology and Genzyme Corporation.

 

Open Orphan 27.75p £185.4m (ORPH.L)

The specialist pharmaceutical services CRO and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces a further contract renewal with a major top-3 global pharmaceutical client extending its consultancy services to end of December 2021. This follows on from the announcement made on 22 December 2020 regarding the same client and demonstrates the repeat business that Venn Life Sciences continues to win from its long-term clients.

 

Equals Group 32.75p £58.5m (EQLS.L)

The technology-led international payments group focused on the SME marketplace, announced a trading update for year ended 31 December 2020.

The Group’s recent trading update on 1 December 2020 noted continuation of positive trading into H2-2020. Since then, the strong performance has continued with revenue for FY-2020 now expected to be around £1.0 million ahead of market expectations at £29.0 million, reflecting a strong performance in the Group’s B2B products in December 2020.  Adjusted EBITDA is now expected to be around £1.0 million for FY-2020, which again is comfortably ahead of market expectations*.

* The Group believes that current market expectations for adjusted EBITDA average £0.55 million with net cash averaging £6.75 million for FY-2020.

 

Tekcapital 16.5p £15.3m (TEK.L)

Portfolio Company Update. Lucyd, the smart eyewear and wearable software developer, has surpassed its US$400,000 crowdfund goal for its subsidiary Innovative Eyewear Inc., and due to on-going investor interest is continuing with the raise up to approximately US$600,000. Additionally, the Company is excited to announce the launch of  Lucyd® Lyte™ . Lucyd Lyte (Lyte) is tech-enhanced, prescription eyewear for active lifestyles, that look and feel like designer fashion frames. Lyte represents an industry leading form-factor for tech glasses, coupled with the miniaturization of components and extended battery life. Lyte e-glasses enable wearers to seamlessly play music, take phone calls and chat with their phone’s assistant while maintaining situational awareness with open-ear technology. High-gloss acetate front plates enable stylish, clear front variants that further reduce the weight of the frames which is important for all-day wear.

 

Advanced Oncotherapy 41.5p £138.4m (AVO.L)

The developer of next-generation proton therapy systems for cancer treatment announced a partnership agreement with DiaMedCare AG, the globally active asset financing partner in the life sciences and other innovative technology sectors. Under the terms of the agreement, Advanced Oncotherapy will be able to offer its customers easier access to the Company’s LIGHT system through a flexible financing solution that reduces the need for large initial upfront payments from customers. The partnership agreement will cover projects in Europe and the United States, in line with the Company’s aim to democratise proton beam therapy.

This partnership is a key step forward in the Company’s commercialisation strategy as it offers Advanced Oncotherapy’s customers the opportunity to access LIGHT systems at a much more affordable price. DiaMedCare’s leasing solutions work very well with Advanced Oncotherapy’s business model, given LIGHT’s modularity and easy installation. This partnership will allow for the democratisation of proton therapy by deploying LIGHT systems in smaller clinics and urban environments compared with other systems on the market that require large installation sites and significant shielding.

 

Head Chef:

Derren Nathan
0203 764 2344
derren.nathan@hybridan.com

*A corporate client of Hybridan LLP

Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.